SAN DIEGO, CA – September 28, 2026 (STL.News) Viking Therapeutics Inc. is facing renewed scrutiny from shareholder attorneys as the biotechnology company advances its closely watched obesity drug candidate, raises hundreds of millions of dollars in new capital, and battles a separate licensing lawsuit involving other drugs in its development pipeline. Kuehn Law PLLC said Monday, Sept. 28, that it is investigating whether certain Viking Therapeutics officers and directors breached their fiduciary duties to shareholders. The shareholder litigation firm said its investigation concerns potential self-dealing and is seeking contact with long-term shareholders of Viking Therapeutics, which trades on Nasdaq
Source: Read Original Article
